Skip to content
Study details
Enrolling now

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Baylor College of Medicine
NCT IDNCT04740580ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

52

Study length

about 4.9 years

Ages

55–85

Locations

1 site in TX

What this study is about

Researchers are testing whether supplementing glycine and N-acetylcysteine or alanine as a placebo affects brain metabolism, inflammation, and cognition in people with Alzheimer's disease. The trial will last for 1780 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Alanine
  • 2.Glycine
  • 3.N-acetylcysteine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralOral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Therapeutic Nutrients/Minerals/Electrolytes (Biological Macromolecular Activity), glycine, acetylcysteine

Drug routes

oral (Oral Capsule)

Endpoints

Primary: Cognition

Secondary: Activities of daily living

Body systems

Neurology